Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 15,400 shares, a drop of 23.0% from the May 15th total of 20,000 shares. Based on an average daily volume of 29,000 shares, the short-interest ratio is currently 0.5 days. Approximately 2.0% of the company’s shares are short sold.
Tharimmune Stock Performance
THAR opened at $3.35 on Friday. Tharimmune has a 12-month low of $2.75 and a 12-month high of $163.09. The stock has a fifty day moving average of $5.25 and a 200-day moving average of $6.41.
Tharimmune (NASDAQ:THAR – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($2.85) earnings per share (EPS) for the quarter.
Tharimmune Company Profile
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Articles
- Five stocks we like better than Tharimmune
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MarketBeat Week in Review – 6/10 – 6/14
- Short Selling: How to Short a Stock
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- Business Services Stocks Investing
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
